Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe active disease with presence of at least 4 tender joints and 4 swollen joints.~* Either the patient or a designee must be capable of administering the subcutaneous injection of study drug.~Exclusion Criteria:~* Prior treatment with etanercept.~* Presence of active infection or active or untreated tuberculosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ETN 50mg QW (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).